Biomarin Pharmaceutical Inc (BMRN)
BioMarin Pharmaceutical Inc. is a biotechnology company focused on developing and commercializing therapies for life-threatening rare diseases and related medical conditions. Its commercial portfolio includes VIMIZIM for MPS IV type A, VOXZOGO for achondroplasia, NAGLAZYME for MPS VI, PALYNZIQ to help reduce blood phenylalanine levels, BRINEURA for CLN2 disease, ALDURAZYME, and KUVAN for phenylketonuria. The company is also advancing product candidates such as BMN 333, a longer-acting CNP being studied for growth disorders including achondroplasia and hypochondroplasia, and BMN 351 for Duchenne muscular dystrophy. BioMarin serves customers through specialty pharmacies, hospitals, non-U.S. government agencies, distributors, and pharmaceutical wholesalers, and it maintains license and collaboration agreements, including with Ares Trading S.A. Incorporated in 1996 and based in San Rafael, California, BioMarin operates across the United States, Europe, Latin America, the Middle East, the Asia Pacific, and other international markets.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-BMRN
|
$72.18
|
29.0% Upside
|
Undervalued
|
$91.56
|
63.6% Upside
|
Bargain
|
Great
|
0.0%
|
148.4x
|
1.7x
|
3.2x
|
10.83 B
|
14.159 B
|
28.1%
|
99.5%
|
2.5
|
1,011.6%
|
